OrthoPediatrics Q2 revenue rises 15%, beats estimates

Orthopediatrics

04/08/2026 21:28

Overview
Pediatric orthopedics firm's Q2 revenue rose 15% yr/yr, beating analyst expectations
Q2 adjusted EBITDA beat analyst expectations
Company raised full-year 2026 revenue guidance, citing strong Trauma & Deformity growth

Outlook
OrthoPediatrics raises 2026 revenue guidance to $265.0 mln-$269.0 mln from $263.0 mln-$267.0 mln
Company expects 2026 adjusted EBITDA of about $25.0 mln and breakeven free cash flow
OrthoPediatrics says operating profile expected to improve, driven by product innovation

Result Drivers
TRAUMA & DEFORMITY GROWTH - Co said Q2 revenue growth was primarily driven by global Trauma & Deformity and OPSB product sales, with multiple product lines contributing
INTERNATIONAL VOLUME - Co attributed international revenue growth to increased procedure volumes and limited set sales
SCOLIOSIS DECLINE - Co said Q2 scoliosis revenue fell due to lower 7D Technology sales and fewer international set sales, partially offset by higher Response fusion revenue and Verteglide addition

Company press release: ID:nGNX8xgS10

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$70.50 mln
$68.25 mln (9 Analysts)
Q2 Loss Per Share
 
$0.30
 
Q2 Net Loss
 
$7.20 mln
 
Q2 Adjusted EBITDA
Beat
$6.80 mln
$6.66 mln (7 Analysts)
Q2 Gross Margin
 
74.00%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for OrthoPediatrics Corp is $24.00, about 15% above its August 3 closing price of $20.87

Reuters Recommended Reads
Aug 3 - SI-BONE Q2 revenue beats estimates, raises 2026 revenue outlook
Aug 4 - UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)